GET DAILY SIGNALSWhy Is Sanuwave Health (SNWV) Stock Down -11.87% Today?
Key Takeaways
- SNWV shares fell roughly 11.87% intraday, trading near $1.93 versus a prior close of $2.19.
- The primary catalyst is continued fallout from a final CMS reimbursement ruling that cut the 2027 Medicare rate for the company's flagship UltraMIST therapy by about 21%.
- Secondary pressure stems from withdrawn fiscal 2026 guidance, a Nasdaq listing-compliance notice, and elevated volatility in a low-float small-cap.
- The decline extends a multi-day selloff that erased the majority of the stock's value in a single session last week.
- Traders are watching the company's third-quarter results and conference call for its response to the reimbursement change.
- Explore more on Price Targets, Earnings, and Forecast for SNWV.
- Discover the strongest-performing automated strategies on the Trending AI Robots page.
Opening Summary
Sanuwave Health, Inc. (SNWV), an Eden Prairie, Minnesota-based medical device company that develops and commercializes non-invasive ultrasound and shockwave technologies for wound care and regenerative medicine, extended its steep decline on Monday. The stock was down about 11.87%, trading near $1.93 after closing the prior completed session at $2.19. The selling reflects investor unease over a recently finalized Medicare reimbursement cut for the company's core UltraMIST product, compounding a sharp selloff that began last week.
Reimbursement Ruling Hits the Core Product
The dominant driver behind the weakness is the U.S. Centers for Medicare & Medicaid Services (CMS) final 2027 Medicare Physician Fee Schedule. The company disclosed that CMS set a reimbursement rate of $314.54 for CPT code 97610 — the code covering its UltraMIST low-frequency, non-contact ultrasound therapy used to treat acute and chronic wounds. That represents a reduction of roughly 21% from the 2026 rate of $397.81. A lower rate directly pressures the economics of physician-office-based treatments, which are central to UltraMIST's recurring, consumables-driven revenue model.
The ruling landed near the low end of what management had flagged as a risk. Earlier guidance had referenced a proposed cut toward roughly $316, and the final figure came in slightly below that. While the hospital outpatient rate for the same code was set at $235.04, an increase of about 15% versus the prior $204.98, investors have focused on the physician-office reduction, which threatens a key channel for the product. Management said it is evaluating options for continued response to the rule.
Withdrawn Guidance and Listing Risk Add to Pressure
Beyond the reimbursement decision itself, broader uncertainty has weighed on sentiment. The company previously withdrew its fiscal 2026 revenue guidance, citing the regulatory unpredictability created by the CMS proposal, and signaled it would not reinstate guidance until there is greater clarity. A loss of forward visibility can amplify selling in small-cap names where investors rely heavily on management's outlook.
Compounding the issue, the company disclosed in late September 2026 that it had received a Nasdaq listing-compliance notice because the market value of its listed securities fell below the $50 million minimum for 30 consecutive business days. A delisting threat adds a layer of structural risk that can deter institutional and retail buyers alike, contributing to sustained downside in a thinly traded stock.
Market Context and Trading Activity
The move reflects an idiosyncratic, company-specific shock rather than broad-market weakness. The stock's steep decline began on November 5, when it fell from a prior close of $5.73 to roughly $2.25 on exceptionally heavy volume, and it has remained under pressure since. The stock's 52-week range now spans from about $1.82 to $36.20, underscoring the scale of the drawdown and the technical damage inflicted on the chart.
Given a market capitalization of only tens of millions of dollars and a relatively small float, SNWV is prone to outsized swings on modest trading flows. The breakdown through key support levels in recent sessions removed prior price floors, and the absence of stabilizing buyers has left the shares searching for a new base well below their recent averages.
What Comes Next for SNWV
The immediate focus turns to the company's third-quarter 2026 financial results, which are expected to be reported after the close on November 10, followed by a conference call on November 11. Investors will listen closely for how management plans to respond to the CMS ruling, whether it intends to contest or adapt to the lower rate, and any update on the status of the Nasdaq compliance matter.
Key uncertainties include whether the reimbursement decision can be moderated, how the change affects UltraMIST system sales and consumables volumes in future quarters, and whether the company can preserve its recurring-revenue growth while navigating a more challenging pricing environment. Any commentary on liquidity, cost controls, or strategic alternatives could also move the shares, given the stock's elevated volatility and reduced price level.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of the platform's strongest-performing automated trading bots under current market conditions. Tickeron offers hundreds of AI-driven bots covering thousands of tickers, with strategies that differ by approach, timeframe, performance metrics, and the symbols they trade. Only the top performers are featured in this section, making it a useful starting point for traders exploring systematic, data-driven approaches to navigate volatile markets.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for SNWV shows an upward move is likely
SNWV's Aroon Indicator triggered a bullish signal on October 21, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 83 similar instances where the Aroon Indicator showed a similar pattern. In 74 of the 83 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +15.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNWV advanced for three days, in 160 of 195 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
SNWV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SNWV as a result. In 122 of 128 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for SNWV turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 65 similar instances when the indicator turned negative. In 63 of the 65 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
SNWV moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SNWV crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNWV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.760) is normal, around the industry mean (4.142). P/E Ratio (1.230) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.873) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. SNWV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNWV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement